Feed / MNKD

MannKind Corporation

MNKD

Healthcare · 3.82 -2.8% today

Isolated · not yet confirmedMarket checked 11 Sept, 09:30 GMT-4

Market read

MannKind Corporation's current read is isolated; its market group is not confirming.

No new filing conclusion is available. 0 of 27 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 9 directly disclosed connections are confirming.

Company-2.8% todayVolume comparison unavailable
Market group0 of 27 activeOil & Gas Exploration · unavailable
Disclosed network0 of 8 confirmingNo filing-linked name is confirming now
What would change this read
  • MNKD's market-adjusted activity becomes unusual and at least one connected name confirms.

Invalidation: The isolated read changes if MNKD's group or a disclosed connection begins moving with it.

Watch this read

Research brief

The story so far

Healthcare · Biotechnology

No new filing conclusion is available. 0 of 27 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 9 directly disclosed connections are confirming.

Evidence that supports

No thresholded supportive filing evidence is available yet.

Evidence that challenges

No thresholded adverse filing evidence is available yet.

What would clarify the read
  • MNKD's market-adjusted activity becomes unusual and at least one connected name confirms.

Company research

Understand the business, not just the ticker

As of Sep 11, 2026
Business model and earnings drivers

Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.

Key research questions
  • Which operating variable is changing?
  • Is that change durable, cyclical or one-off?
  • What evidence would disprove the current interpretation?
Annual periods9
Price observations319
Usable filing statements151
Verified relationships8
Evidence supporting the case
  • Latest annual revenue changed +22.2% year over year.
  • Operating cash flow covered net income at 3.11x in the latest annual period.
Evidence challenging the case
  • Operating margin changed -14.3 percentage points in the latest annual period.
  • Net margin changed -8.0 percentage points in the latest annual period.
  • Diluted shares increased 10.7% in the latest annual period.
  • Demand and volume has repeated adverse evidence across 3 filings.
Questions before a position

No credible peer-relative valuation comparison is available yet.

Longer-term price context

Price as of Sep 10, 2026

3.80
6m+15.7%12m-16.0%24m
Annual trajectory

Reported annual revenue and per-share history. This is accounting history, not a forecast.

PeriodRevenueYoYDiluted EPSShare change
2021-12-31$75.4M+15.8%$-0.32+12.0%
2022-12-31$99.8M+32.2%$-0.34+3.1%
2023-12-31$199.0M+99.4%$-0.04+3.9%
2024-12-31$285.5M+43.5%$0.10+6.3%
2025-12-31$349.0M+22.2%$0.02+10.7%

What management says matters

Persistent and emerging business drivers

Credit and interest ratesnegative · 4 filings
As a result of the PSA, transaction costs totaling $ 4.4 million (including the Reimbursements) are reported net of the Royalty Liability balance and amortized to interest expense in the condensed consolidated statements of operations over the life of the PSA…
10-Q · May 6, 2026
Demand and volumenegative · 3 filings
V-Go — Gross revenue from sales of V-Go decreased by $11.0 million, or 30%, for the year ended December 31, 2025 compared to the prior year and was primarily a result of lower demand partially offset by lower gross to net deductions.
10-K · Feb 26, 2026
Foreign exchangenegative · 3 filings
Gain on foreign currency transaction was $1.3 million for the three months ended March 31, 2026 compared to a loss of $2.5 million for the same period in the prior year due to fluctuations in Euro to U.S.
10-Q · May 6, 2026
Legal and regulatory exposuremixed · 2 filings
The maximum aggregate amount payable with respect to the CVRs issued at the closing of the acquisition is $59.7 million, subject to the achievement of certain regulatory and net sales milestones on or prior to the applicable milestone outside dates in accorda…
10-Q · May 6, 2026

Valuation discipline

Peer-relative valuation withheld

Jodie found no industry-matched filing peers suitable for a valuation comparison. It will not substitute broader financial-sector names.

Scenario scaffold

Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.

Price action

How the market is pricing the story

3.82-2.8% today

Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 09:30 GMT-4; this is a coverage limitation, not a flat-price conclusion.

Developments

No sourced recent-development timeline yet

Jodie has not returned a relevant primary source or news item for MNKD. This is an evidence-coverage gap, not a conclusion that nothing material happened.

Business and financial condition

Reported financial figures are not available yet

Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.

Filing analysis

No comparable filing assessment is available yet

Jodie has not yet found a suitable current-versus-prior filing comparison for MNKD. This does not mean the latest filing was neutral or immaterial.

Business ecosystem

The relationships behind MNKD

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

BXBlackstone Inc.lenderMay 6, 2026

The Blackstone Credit Facility requires us to maintain at least $40.0 million of liquidity, tested quarterly, with liquidity defined as our unrestricted cash and cash equivalents held in collateral accounts of the lenders.

UTHRUnited Therapeutics CorporationpartnerMay 6, 2026

United Therapeutics License Agreement — In September 2018, the Company and UT entered into an exclusive global license and collaboration agreement (the “UT License Agreement”), pursuant to which UT is responsible for global development, regulatory and commerc…

Depended on by

AMPHAmphastar Pharmaceuticals, Inc.partnerFeb 26, 2026

arily related to the expansion of our sales and marketing efforts related to BAQSIMI ® , including expenses related to our co-promotion contract with MannKind, and sales efforts related to Primatene MIST ® .

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 8 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

MNKD is currently a Follower in the organic co-movement group Oil & Gas Exploration. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.

This group is retained as the last observed read for MNKD; it is not active in the latest market snapshot.

Context history

Theme membership history

No durable theme membership has been observed for this name yet.